Antibody Decay, T Cell Immunity and Breakthrough Infections Following Two SARS-CoV-2 Vaccine Doses in Inflammatory Bowel Disease Patients Treated with Infliximab and Vedolizumab

The authors reported SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who were treated either with an anti-tumor necrosis factor antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that did not impair systemic immunity.